From: Pregabalin in fibromyalgia - responder analysis from individual patient data
 |  | Percent with treatment/placebo | NNT (95% CI) | |||||
---|---|---|---|---|---|---|---|---|
Outcome | Level | Placebo | 300 mg | 450 mg | 600 mg | 300 mg | 450 mg | 600 mg |
Pain: change from baseline | ≥ 0% | 60 | 65 | 68 | 60 | not calculated | 13 (8.0 to 41) | not calculated |
6 weeks | ≥ 15% | 44 | 52 | 56 | 52 | 13 (7.8 to 43) | 8.4 (5.8 to 15) | 14 (7.6 to 67) |
 | ≥ 30% | 28 | 36 | 39 | 39 | 10 (6.9 to 21) | 8.0 (5.7 to 13) | 8.5 (5.8 to 16) |
 | ≥ 50% | 14 | 21 | 23 | 26 | 14 (8.8 to 30) | 12 (7.9 to 22) | 8.8 (6.2 to 15) |
 | ≥ 70% | 4.1 | 7.7 | 9.0 | 12 | 30 (17 to 110) | 19 (13 to 38) | 14 (9.8 to 26) |
Pain: change from baseline | ≥ 0% | 54 | 55 | 60 | 53 | not calculated | not calculated | not calculated |
12 weeks | ≥ 15% | 40 | 45 | 49 | 43 | not calculated | 12 (6.9 to 35) | not calculated |
 | ≥ 30% | 29 | 33 | 38 | 34 | not calculated | 11 (6.9 to 29) | not calculated |
 | ≥ 50% | 15 | 19 | 21 | 23 | 22 (11 to 870) | 16 (9.3 to 59) | 13 (8.1 to 31) |
 | ≥ 70% | 5.9 | 6.8 | 8.5 | 12 | not calculated | not calculated | 18 (11 to 43) |
Sleep: change from baseline | ≥ 0% | 59 | 64 | 68 | 61 | not calculated | 11 (7.0 to 23) | not calculated |
6 weeks | ≥ 15% | 45 | 53 | 55 | 51 | 11 (7.2 to 29) | 9.3 (6.3 to 18) | 15 (8.0 to 130) |
 | ≥ 30% | 29 | 39 | 43 | 41 | 9.4 (6.4 to 17) | 6.8 (5.1 to 10) | 8.2 (5.7 to 15) |
 | ≥ 50% | 13 | 25 | 26 | 26 | 9.0 (6.6 to 14) | 7.8 (5.9 to 12) | 7.7 (5.7 to 12) |
 | ≥ 70% | 3.8 | 11 | 13 | 13 | 14 (10 to 23) | 11 (8.6 to 17) | 12 (8.8 to 21) |
Sleep: change from baseline | ≥ 0% | 51 | 54 | 58 | 52 | not calculated | 14 (7.6 to 68) | not calculated |
12 weeks | ≥ 15% | 37 | 43 | 49 | 44 | not calculated | 8.9 (5.9 to 19) | 16 (8.3 to 170) |
 | ≥ 30% | 25 | 32 | 40 | 35 | 14 (8.1 to 58) | 7.0 (5.1 to 11) | 10 (6.6 to 22) |
 | ≥ 50% | 14 | 21 | 26 | 26 | 13 (8.2 to 30) | 8.4 (6.0 to 14) | 8.4 (6.1 to 14) |
 | ≥ 70% | 5.0 | 9.3 | 10 | 12 | 24 (14 to 82) | 20 (13 to 55) | 14 (9.4 to 24) |